NEWS

NEWS

CONNECTA Therapeutics selected for funding under the EIC Accelerator

The European Innovation Council (EIC) announced yesterday that CONNECTA Therapeutics has been selected for grant and equity funding, following the last EIC Accelerator cut-off. CONNECTA Therapeutics is honored to be part of the 71 European companies selected among 1211 submitted proposals in the most competitive funding round…

CONNECTA Therapeutics, CRG, Hospital del Mar Research Institute and I3PT receive €2.7 million from the Spanish Ministry of Science and Innovation to begin Phase IIa trials for CTH120 in Fragile X syndrome

The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment. María Martínez, Jordi Fàbrega, Mara Dierssen, Ana Aldea, Rafael de la Torre and Ana Roche…